Search

Displaying results 1981 - 1990 of 10000 in total
  1. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  2. Drug

    Nemonoxacin

    go.drugbank.com/drugs/DB06600
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Inhibitors
  3. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.

    Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  4. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D). … [A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on

  5. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … It is currently available under the brand name Removab.

  6. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.

    Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet)
  7. Drug

    Aplindore

    go.drugbank.com/drugs/DB06620
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  8. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). … [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  9. Drug

    N-chlorotaurine

    go.drugbank.com/drugs/DB06633
    Experimental

    N-chlorotaurine is an inhibitor of inducible nitric oxide synthase and IkappaB kinase.

    Synonyms: N-chlorotaurine, N-monochlorotaurine
  10. Drug

    Casopitant

    go.drugbank.com/drugs/DB06634
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring, Neurokinin-1 Receptor Antagonists